Quarterly report pursuant to Section 13 or 15(d)

Summary Significant Accounting Policies Parentheticals (Details)

v2.4.0.6
Summary Significant Accounting Policies Parentheticals (Details) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Amortization of deferred financing costs $ 0 $ 4,284
Costs of patents written off (ProAlgaZyme) 6,234 0
Research Expenses - Salaries and equipment related expenses 25,000 25,000
Clinical Studies expenses - fees, charges and related expenses 104,000 77,000
Compensation expenses recorded 6,037 10,722
Advertising/Public Relation costs charged to operating expenses $ 7,461 $ 9,496